☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Abbvie
AbbVie Reports the US FDA’s Approval of Botox Cosmetic (OnabotulinumtoxinA) for Moderate to Severe Vertical Bands Connecting the J...
October 21, 2024
AbbVie Reports the US FDA’s Approval of Vyalev (Foscarbidopa and Foslevodopa) for Treating Advanced Parkinson's Disease
October 18, 2024
AbbVie Seeks the US FDA’s Accelerated Approval of Telisotuzumab Vedotin (Teliso-V) for Treating Non-Squamous NSCLC
September 30, 2024
AbbVie Reports Topline Data from P-III (TEMPO-1) Study of Tavapadon Alone for Parkinson's Disease
September 27, 2024
AbbVie Reports the CHMP’s Positive Opinion of Elahere (Mirvetuximab Soravtansine) to Treat Ovarian Cancer
September 23, 2024
AbbVie Receives EC’s Conditional Marketing for Tepkinly (Epcoritamab) to R/R Follicular Lymphoma (FL)
August 22, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.